Intraocular Pressure Elevation After Suprachoroidal Triamcinolone Acetonide in Noninfectious Uveitis: An IRIS® Registry Study.
Suprachoroidal triamcinolone acetonide is associated with a higher rate of intraocular pressure elevation.
Intraocular Pressure Elevation After Suprachoroidal Triamcinolone Acetonide in Noninfectious Uveitis: An IRIS® Registry Study.
To evaluate the incidence of intraocular pressure (IOP) elevation and glaucoma-related complications after suprachoroidal triamcinolone acetonide (SCS-TA) injection in patients with noninfectious uveitis (noninfectious uveitis) using real-world data from the IRIS® Registry.
Adults with noninfectious uveitis recorded in the American Academy of Ophthalmology IRIS® Registry who received SCS-TA, a dexamethasone intravitreal implant (DEX), or systemic immunosuppressive therapy without local corticosteroid (corticosteroid) treatment.
SCS-TA treatment makes eye pressure reaching 24 mmHg over twice as likely
A total of 790 eyes treated with SCS-TA were matched to 790 DEX-treated eyes and 790 control eyes.
The SCS-TA group received a mean of 0.6 additional SCS-TA injections and 1.0 total corticosteroid injections, compared with 1.0 DEX injections and 1.2 total corticosteroid injections in the DEX group.
IOP-lowering medication use increased in both corticosteroid groups during follow-up.
Glaucoma surgery occurred at crude 12-month rates of 2.0% for SCS-TA, 1.1% for DEX, and 1.4% for controls, with no significant differences between groups (SCS-TA: HR 1.33, 95% CI 0.62-2.86, P=0.469; DEX: HR 0.74, 95% CI 0.31-1.78, P=0.50).
In this large real-world cohort of patients with noninfectious uveitis, both SCS-TA and DEX were associated with higher risks of clinically significant IOP elevation compared with systemic therapy controls, with broadly similar incidence between the two corticosteroid delivery approaches.
Although IOP-lowering medications were more frequently required, the overall incidence of glaucoma surgery remained low.